Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06466564
Other study ID # SSTH-2023-02-0A
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 24, 2023
Est. completion date June 1, 2026

Study information

Verified date June 2024
Source MicroPort NeuroTech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The scope of this trial is the collection and analysis of effectiveness and safety endpoints, related to the use of the Bioabsorbable/Nufairy Coil Embolization System in the treatment of intracranial aneurysms.


Description:

Approximately 258 subjects with intracranial aneurysms would be enrolled for coiling embolization according to the inclusion and exclusion criteria specified in this trial protocol. Subjects were evaluated by mRS preoperatively, at the time of device implantation, at the time of discharge from the hospital, at 1 month (±7 days) postoperatively, at 6 months (±30 days) postoperatively, and at 12 months (±90 days) postoperatively; subjects would underwent DSA imaging at surgery and at 12months (±90 days) postoperatively, and MRA imaging at 18 months (±90 days) postoperatively. Unplanned follow-up of the subjects would performed when necessary, and data would be recorded to evaluate the safety and efficacy of Nufairy Coil Embolization System for coiling embolization for the treatment of intracranial aneurysms.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 258
Est. completion date June 1, 2026
Est. primary completion date October 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female =18 years old and =80 years old at the time of signing the informed consent; 2. Intracranial aneurysm diagnosed by CTA, MRA, DSA neuroimaging examination; 3. Subjects whose target aneurysms are suitable for embolization with flow diverter or intracranial arterial stents assisted by coils, and the entire treatment can be performed in a single procedure; 4. The subjects or the subject's guardian signs the informed consent voluntarily and is willing to accept follow-up. Exclusion Criteria: 1. mRS Score =3 points in clinical assessment prior to enrollment; 2. Subjects who received neurosurgical or endovascular treatment for recurrent aneurysms; 3. Subjects with multiple aneurysms; 4. Subjects with ruptured aneurysms <30 days; 5. Significant stenosis (=50%) of parent artery; 6. Subjects who are not suitable for anesthesia or intravascular surgery, such as major diseases of the heart, lung, liver, spleen, kidney, brain tumors, severe active infections, disseminated intravascular coagulation, and a history of serious mental illness; 7. Subjects who have undergone major surgical procedures (such as internal fixation device implantation of limbs fracture, tumor resection, major organ surgery, etc.) within 30 days before signing the informed consent or plan to undergo major surgical procedures within 60 days after signing the informed consent; 8. Subjects with morphology or lesions that may interfere with device use, including but not limited to: carotid artery dissection, vasculitis, aortic dissection, limited vascular access (e.g., severe intracranial vessel tortuosity, severe intracranial vessel spasm that does not respond to medical treatment, other anatomical or clinical changes that impede device access; 9. Treatment contrainidations of coils, including but not limited to: contrainidations of digital subtraction angiography, allergy to or intolerance of contrast agents, allergy to or intolerance of anti-platelet and anticoagulant drugs required for treatment, platinum-tungsten alloy, and poly(co-glycolic acid) (PLGA); 10. Pregnant or lactating women; 11. Life expectancy is less than 18 months; 12. Subjects participating in other drug or device studies did not meet the endpoint.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nufairy® Coil embolization system for intracranial aneurysm
Nufairy® Coil embolization system for intracranial aneurysm

Locations

Country Name City State
China Shanghai Changhai Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
MicroPort NeuroTech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Successful occlusion rate of aneurysm at 18-month post-procedure. It was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I or II (i.e., 95%-100% aneurysm embolization). 18 month
Other Recurrence rate of aneurysm at 18-month post-procedure. The "recurrence rate of aneurysm" was defined as the percentage of subjects with a decrease in the degree of aneurysm embolization at the follow-up visit as compared with immediately post-procedure. 18 month
Other Retreatment rate of aneurysm at 18-month post-procedure. The "retreatment of aneurysm" was defined as the percentage of subject who received retreatment for the recurrence of target aneurysms during the follow-up period 18 month
Other The incidence of ipsilateral stroke or neurologic death of the target aneurysm within 18 months. 18 month
Other Device-related serious adverse events at 18 months after surgery 18 month
Primary Successful occlusion rate of aneurysm at 12-month post-procedure. It was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I or II (i.e., 95%-100% aneurysm embolization). 12 month
Secondary Complete occlusion rate of aneurysm at 12-month post-procedure. The "complete occlusion rate of aneurysm" was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I (i.e., 100% aneurysm embolization). 12 month
Secondary Recurrence rate of aneurysm at 12-month post-procedure. The "recurrence rate of aneurysm" was defined as the percentage of subjects with a decrease in the degree of aneurysm embolization at the follow-up visit as compared with immediately post-procedure. 12 month
Secondary Retreatment rate of aneurysm at 12-month post-procedure. The "retreatment of aneurysm" was defined as the percentage of subject who received retreatment for the recurrence of target aneurysms during the follow-up period 12 month
Secondary Device-related serious adverse events at 1, 6, and 12 months after surgery; 12 month
Secondary The incidence of ipsilateral stroke or neurologic death of the target aneurysm within 12 months. 12 month
Secondary The incidence of ipsilateral ischemic stroke of the target aneurysm within 12 months. 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT04870047 - Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation N/A
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT05665309 - Interest of Pre-operative Use of 3D Printing for Endovascular Treatment of Unruptured Intracranial Aneurysms With Intrasaccular Flow Disruptor N/A
Completed NCT02783339 - Neuroform Atlas Stent for Intracranial Aneurysm Treatment
Withdrawn NCT01194388 - Axium Coil in Completing Endovascular Aneurysm Surgery Study
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Recruiting NCT05409989 - MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study N/A
Completed NCT03680742 - Contour Neurovascular System - European Pre-Market Unruptured Aneurysm N/A
Completed NCT04872842 - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on 100 Regional Medical Centers in China and Population Follow-up Study
Terminated NCT02532517 - Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device N/A
Completed NCT03663257 - Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
Recruiting NCT06189950 - Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE N/A
Recruiting NCT05608122 - Establishment of Online Registration Platform for Unruptured Intracranial Aneurysms Based on Regional Medical Centers in China and Population Follow-up Study (Phase Ⅱ)
Recruiting NCT03661463 - Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT). Phase 2
Completed NCT02609867 - A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise) N/A
Active, not recruiting NCT02292017 - Prospective Packing Density With Target Coils I N/A
Active, not recruiting NCT01872741 - Minipterional Versus Pterional Craniotomy N/A
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Completed NCT00777907 - Complete Occlusion of Coilable Aneurysms Phase 3
Completed NCT00777088 - Pipeline for Uncoilable or Failed Aneurysms N/A